AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
CHORIOGONADOTROPIN ALFA
4 registrations across 3 African markets— 4 active
Markets with CHORIOGONADOTROPIN ALFA
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Ovitrelle 250 micrograms Solution for Injection in Prefilled Syringe** Solution for injection | 🇳🇬Nigeria | Merck Pharmaceutical and Life Sciences Limited | active | Dec 2027 |
| OVITRELLE 250mg/0.5ml SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE (CHORIOGONADOTROPIN ALFA) | 🇬🇭Ghana | — | active | Jun 2027 |
| OVITRELLE 250mg/0.5ml SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE (CHORIOGONADOTROPIN ALFA) | 🇬🇭Ghana | — | active | Jun 2027 |
| OVITRELLE 250 ug/0,5 ml | 🇿🇦South Africa | Merck (Pty) Ltd | active | Jan 1900 |
CHORIOGONADOTROPIN ALFA in Africa — Regulatory Overview
CHORIOGONADOTROPIN ALFA is registered across 3 African markets with 4 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Nigeria, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 4 registrations, 4 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.